Thank you all for your excellent participation so far. This question will mark the halfway point in our discussion. In the accompanying NEJM editorial by Dr. Connors, she notes that nonneutralizing antibodies were seen in 17% of participants, and observes that this may have an impact on subsequent administration of andexanet. As we all know, patients who have bleeding events, often have re-bleeding events, and it is not unlikely that a patient will need to receive multiple treatments with adnexanet. If there is a concern that adnexanet may have decreasing efficacy after the inital dose, this may lead clinicians to switch to warfarin or dabigatran after a bleeding event on rivaroxaban or apixaban. Can you please comment on the importance of these antibodies and whether they will likely be clinically important.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.